return equiti ttm
third-quart jakafi slight miss bottom-lin soft guidanc
pipelin catalyst sight
tuesday octob market open report third quarter
continu execut commerci front balanc
drive near-term profit growth realiz long-term growth
financi result exhibit total revenu quarter million line
estim million consensu million jakafi net product revenu
unit state million estim million consensu
million jakafi product revenu miss partli attribut
million inventori destock quarter expect normal
futur quarter iclusig revenu record million slightli
estim million consensu million quarter record
million olumi royalti sale europ bottom line non-
net incom quarter million estim million
consensu million non-gaap ep estim
consensu end quarter billion cash cash equival
complet varianc analysi expect consensu actual result
summar exhibit despit slight miss third quarter compani updat
jakafi guidanc increas lower end rang result net revenu
guidanc billion billion
deep pipelin regulatori catalyst includ potenti approv jakafi
steroid-refractori graft-versus-host diseas gvhd add jakafi growth nda
submiss pemigatinib refractori cholangiocarcinoma well nda submiss
capmatinib nonsmall-cel lung cancer nsclc partner novarti nv
entitl mileston royalti sale pivot data catalyst
includ jakafi itacitinib variou gvhd phase studi look occupi
frontlin steroid-refractori set gvhd two agent potenti
approv pemigatinib pivot data bladder cancer phase data baricitinib
atop dermat partner number pivot studi
initi well exhibit void left epacadostat larg
look gradual fill void five novel candid enter market next
five year compani continu pursu strategi extend jakafi life-cycle explor
combin in-hous agent pim inhibitor itacitinib inhibitor
inhibitor combin design improv treatment
success serv build base busi myeloprolif neoplasm
mpn beyond patent expir jakafi compani also run
addit program deep pipelin oncolog candid includ inhibitor
fgfr pemigatinib well immunolog candid inhibit
base wilmington delawar major oncology-focus biotechnolog compani
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
thought valuat share continu forecast billion peak sale jakafi higher
billion compani guidanc believ jakafi doubl combo could extend franchis
significantli current valuat reflect jakafi franchis rheumatoid arthriti ra indic olumi
franchis partner iclusig revenu includ jakafi compani six agent clinic develop
repres potenti new indic launch next five year provid substanti upsid opportun exhibit
look includ agent well addit indic expans compani market product
valuat futur data read exhibit believ consist profit pipelin success next
month could start drive valu share recov epacadostat franchis setback probability-
adjust net present valu npv model assign per share jakafi per share iclusig per share
olumi ad per share net cash year-end arriv fair valu assess share
manag increas bottom end jakafi sale guidanc updat billion billion
billion billion previous repres increas midpoint
slightli lower estim billion billion previous near midpoint
guidanc maintain above-guid estim billion peak jakafi sale central
valuat jakafi franchis jakafi came million sequenti growth second quarter
repres growth third quarter jakafi product revenu miss third quarter partli
attribut million inventori destock quarter expect normal futur quarter
note end third quarter patient take jakafi date jakafi penetr
elig myelofibrosi mf popul polycythemia vera pv popul unit
state ampl room growth opinion peak estim jakafi penetr
elig mf popul elig pv popul exhibit jakafi remain approv therapi
indic potenti competitor near-to-medium term
continu execut develop extens pipelin clinic asset includ five novel
candid potenti enter market next five year well strategi continu growth
base busi follow failur studi epacadostat earlier year focu shift toward
compani clinic preclin pipelin program coupl continu commerci growth extens
supplement new drug applic snda jakafi steroid-refractori acut gvhd agvhd accept
fda prioriti review third quarter expect potenti approv
posit top-line data pivot phase ii studi jakafi steroid-refractori agvhd enabl regulatori
submiss third quarter may follow approv current model million
 peak sale gvhd jakafi part billion peak sale estim jakafi franchis
remain studi reach program jakafi steroid-refractori gvhd expect read
run partner novarti on-going phase studi patient steroid-
refractori acut gvhd serv supplement studi full approv also recent began
enrol confirmatori phase studi jakafi steroid-refractori chronic gvhd serv
complet jakafi footprint across steroid-refractori gvhd field
addit strategi extend jakafi life-cycle jakafi also evalu treatment essenti
thrombocytopenia et pivot phase ii studi top-line data estim come
compani also continu explor combin in-hous agent pim inhibitor itacitinib
inhibitor inhibitor combin design improv treatment success
patient inadequ respons jakafi monotherapi serv build base busi
myeloprolif neoplasm mpn beyond jakafi patent expir manag previous
guid sale jakafi fall rang billion take account potenti
growth due novel combin approv novel combin would extend growth jakafi franchis
beyond also provid improv econom sinc combin partner wholly-own
gravita program select inhibitor itacitinib cover steroid-nav prophylact gvhd
set note includ itacitinib assess share success
pipelin candid repres upsid valuat first phase trial itacitinib
seek enrol patient steroid-nav acut gvhd random receiv itacitinib placebo
combin steroid primari endpoint orr day top-lin data expect
success would lead itacitinib first global regulatori submiss second phase studi steroid-nav
chronic gvhd expect initi first half success manag project itacitinib
see approv second indic time frame itacitinib also enter evalu
potenti prophylact treatment phase studi estim top-lin data studi
avail second half
addit jakafi program list run sever clinic trial in-hous agent
could potenti support upsid valuat addit program includ variou oncolog candid
includ inhibitor fgfr well immunolog candid inhibit
candid numer data readout within next year manag believ could help sustain top-
line growth next three five year point includ program valuat look
includ potenti data read competit landscap shake detail program
european societi medic oncolog esmo octob munich compani present interim
result two on-going studi inhibitor pemigatinib treatment
cholangiocarcinoma bladder cancer given data present believ
pemigatinib could best-in-class second-lin cholangiocarcinoma transloc nda file
also believ pemigatinib could like player urotheli carcinoma uc bladder cancer
fusion continu dose pemigatinib set improv potenc see right
transloc preval intrahepat cholangiocarcinoma annual incid
patient unit state eu japan roughli newli diagnos metastatic/unresect uc
patient unit state eu japan fgfr transloc mutat preval
beyond two initi indic expect field move tumor fgfr aberr
cholangiocarcinoma pemigatinib produc orr month second-lin
cholangiocarcinoma transloc cohort patient closest competitor qed
privat infigratinib produc orr month set date
slightli shorter follow metastat surgic unresect uc patient fusion pemigatinib
treatment result orr intermitt dose comparison johnson johnson
erdafitinib demonstr impress orr cr among patient set phase
ii studi note johnson johnson abl improv orr switch
intermitt continu dose follow suit recruit anoth cohort patient
continu dose suspect efficaci would improv well
proof-of-concept data citadel program inhibitor candid anticip
readout treatment relapsed/refractori r/r set follicular lymphoma fl margin
zone lymphoma mzl mantl cell lymphoma mcl compani expect proof-of-concept data
three monotherapi trial fl mzl mcl
respect success studi enabl seek acceler approv support initi phase
program versu standard care indic
compani develop program evalu inhibitor candid
treatment variou malign data expect read
compani seek rapid approv candid select tumor type compani push
develop three initi indic msi-high microsatellit instability-high endometri cancer merkel
cell carcinoma data expect anal cancer data expect compani also
explor synergi multipl larg small molecul intern product candid combin therapi
beyond oncolog data true-derm program topic jakafi treatment vitiligo expect
data phase iib studi topic jakafi treat atop dermat present european
academi dermatolog venerolog eadv annual congress septemb pari ruxolitinib cream
treatment result prompt improv easi iga pruritus/itch associ safeti toler
find regulatori discuss alreadi underway regard phase design await potenti phase
studi initi addit dermatolog program includ inhibitor treatment
hidraden suppurativa inhibitor variou non-oncolog program also
upcom catalyst includ first agent compani bispecif program collabor
meru mru enter clinic near year-end proof concept data margin zone lymphoma
mzl mantl cell lymphoma mcl follicular lymphoma fl dose escal data pim
inhibitor pair biopsi data in-hous combo inhibitor data
potenti approv jakafi steroid-refractori acut gvhd base data
risk market perform rate includ clinic risk pipelin unforeseen competit
jakafi safeti risk olumi
incom royalti iclusig eu epacadostat revenues- contract total expensescost product sg chang fair valu acquisition-rel conting expenses- total oper oper interest incom interest debt exchang expens senior note conversions- unreal loss long term invest loss repurchase/redempt conv senior subordin notes- total incom pre-tax comprehens gain/ loss accret redempt valu redeem conv prefer stock- provis incom net non- reconciliationmileston revenu new exist partners- up-front consider mileston relat partners- non-cash stock comp equiti awards- asset impair in-process chang fair valu conting consideration- amort acquir product rights- chang fair valu equiti investments- non-cash interest exp relat conv notes- expens relat senior note conversions- tax effect non-gaap adjustments- total non- adjustments- non- net income- non- ep diluted- ep weight averag share outstand weight averag share outstand sourc william blair estim compani reportsexhibit corporationincom statement dollar thousand except per william blair
blair estimateswillam blair estimatesactualactualwb estimate actual vs estimate con estactu vs consactu q/q growthcurrentpreviouscurr vs previousy/i growthcurrentpreviouscurr vs previousy/i growthin thousand except per share datarevenuesjakafi net product expens oper net ep william blair estim factset compani reportsexhibit corporationvari analysi compani reportsexhibit corporationobject end
time indic initi submiss seek market approv indic compani reportsexhibit corporationpotenti new product indic launch william blair
drugind statusnotessteroid-refractori acut gvhdsnda accept prioriti review base phase chronic gvhdphase thrombocythemiaphas ii reset refractori myelofibrosisphas ii combin pim itacitinib acut gvhdphase acut gvhdphase begin cell lung cancerphas i/ii combin osimertinib egfr follicular lymphomaphas ii zone lymphomaphas ii cell lymphomaphas ii cancerphas ii ii phase brd advanc malignanciesphas i/ii dose-escalationdevelop discontinu preclin safeti pim hematolog malignanciesphas i/ii dose-escalationdevelop combin jak myeloid leukemia small cell lung cancerphas i/ii dose-escalationepigenet mechan target cell carcinomaphas i/ii greater select initi develop expect focu hepatocellular carcinomaepacadostat cancerphas ii combin keytruda msi-high endometri cancerphas iiexpect begin cell carcinomaphas iiexpect begin cancerphas iiexpect begin arg solid tumor phase i/ii novel mechan target myeloid cell develop expect focu combo gitr solid tumor phase i/ii await proof-of-concept tumor phase i/ii await proof-of-concept axl/mer solid tumor phase i/ii dose-escalationpotenti immune-direct target therapi agent i/ii await proof-of-concept i/ii await proof-of-concept dataatop dermatitisphas phase preparationvitiligophas iihidraden suppurativaphas iirheumatoid arthritisapprov europ japan dose approv doseatop dermatitisphas psoriat arthritisphas lilli expect phase begin lupu erythematosusphas sever alopecia areataphas ii/capmatinib licens novarti non-smal cell lung cancer liver cancerphas ii egfr wild-typ neg nsclc patient amplif mutationsourc compani reportscanc target therapiescanc immun therapiespartn exhibit corporationpipelin progressruxolitinib ruxolitinib william blair
drugpeak salesstag developmentestim launch dateprob commercializationpercentag sale companyprobability-adjust npvvalu per sharepercentag fair marketedapprov nov marketedapprov juli eu marketedapprov februari tier present valu addit william blair estimatessum-of-part fair valu exhibit corporationfair valuenet year-end incid probabl successlaunch dateindicationwb estimate current market sharewb modelpeak shareprice/yeartreat durationpeak salespeak global high-risk myelofibrosi includ primari myelofibrosi post-polycythemia vera myelofibrosi post-essenti thrombocythemia high risk polycythemia vera intoler inadequ respons acut chronic high risk hu intoler essenti thrombocythemia intoler inadequ respons hydroxyurea harbor william blair estim compani reportsexhibit corporationjakafi assumpt import disclosur
